AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22404535 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor (PPI) therapy
Number of subjects: 21
Study 21814211 — intervention group
Group type: EXPERIMENTAL
Intervention: Imidapril 10 mg (titrated to 20 mg for nonresponders)
Number of subjects: 84
Study 21814211 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 16 mg (titrated to 32 mg for nonresponders)
Number of subjects: 84
Study 18157638 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccination in CD patients
Number of subjects: 25
Study 18157638 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis B vaccination in control subjects
Number of subjects: 25
Study 16488084 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine, 5-20 mg/day
Number of subjects: 54
Study 16488084 — intervention group
Group type: COMPARATOR
Intervention: Current therapy (pre-study antipsychotic medication)
Number of subjects: 54
Study 12730468 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary assessment protocols
Number of subjects: 0
Study 12730468 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled trials (RCT)
Number of subjects: 0
Study 12730468 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis
Number of subjects: 0
Study 11867964 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednicarbate
Number of subjects: 0
Study 11867964 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone 17‐valerate
Number of subjects: 0
Study 11867964 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate
Number of subjects: 0
Study 11867964 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study 9456097 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose aprotinin
Number of subjects: 20
Study 9456097 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 8587947 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose drink (160 kcals/40 grams of cane sugar)
Number of subjects: 0
Study 8587947 — intervention group
Group type: COMPARATOR
Intervention: Saccharin or water (control)
Number of subjects: 0
Study 2751592 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.5 mg
Number of subjects: 68
Study 2751592 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 324835 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpropamide (100 mg. O.D.)
Number of subjects: 5
Study 324835 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolbutamide (500 mg. b.i.d.)
Number of subjects: 5
Study 324835 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenformin (50 mg. O.D.)
Number of subjects: 5
Study 324835 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetohexamide (250 mg. O.D.)
Number of subjects: 5
Study 324835 — intervention group
Group type: COMPARATOR
Intervention: Placebo (diet alone)
Number of subjects: 5
Study 31758941 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative regional blocks using 0.25% bupivacaine hydrochloride
Number of subjects: 110
Study 31758941 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard anesthetic and postoperative protocols)
Number of subjects: 110
Study 31021304 — intervention group
Group type: EXPERIMENTAL
Intervention: Child and parent received the prevention interventions
Number of subjects: 487
Study 31021304 — intervention group
Group type: COMPARATOR
Intervention: Only the parent received the prevention intervention
Number of subjects: 487
Study 31021304 — intervention group
Group type: COMPARATOR
Intervention: Neither child nor parent received the prevention interventions
Number of subjects: 487
Study 28426834 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate access to PrEP
Number of subjects: 544
Study 28426834 — intervention group
Group type: COMPARATOR
Intervention: Deferred access to PrEP
Number of subjects: 544
Study 26458896 — intervention group
Group type: EXPERIMENTAL
Intervention: SPARX‐R, an online, gamified intervention based on cognitive behavioural principles
Number of subjects: 1600
Study 26458896 — intervention group
Group type: COMPARATOR
Intervention: lifeSTYLE, an attention‐controlled placebo comparator
Number of subjects: 1600
Study 26458896 — intervention group
Group type: EXPERIMENTAL
Intervention: SPARX‐R
Number of subjects: 1600
Study 26458896 — intervention group
Group type: COMPARATOR
Intervention: lifeSTYLE
Number of subjects: 1600
Study 23530305 — intervention group
Group type: EXPERIMENTAL
Intervention: Living Well By Faith intervention (8-week program, classes held twice a week including educational workshops and exercise sessions)
Number of subjects: 106
Study 23530305 — intervention group
Group type: COMPARATOR
Intervention: Control group (minimal intervention consisting of one educational workshop)
Number of subjects: 106
Study 22078345 — intervention group
Group type: EXPERIMENTAL
Intervention: L-ornithine-L-aspartate (LOLA)
Number of subjects: 120
Study 22078345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 19211452 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (81 to 325 mg/d)
Number of subjects: 2967
Study 19211452 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2967
Study 19211452 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (any dose)
Number of subjects: 2967
Study 16492440 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified maternal milk thickened by 1.5 g of precooked starch per 100 mL of milk (milk B)
Number of subjects: 5
Study 16492440 — intervention group
Group type: COMPARATOR
Intervention: Fortified maternal milk (milk A)
Number of subjects: 5
Study 14687309 — intervention group
Group type: EXPERIMENTAL
Intervention: CVT‐E002 (200 mg, oral, twice daily)
Number of subjects: 198
Study 14687309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study 10930901 — intervention group
Group type: EXPERIMENTAL
Intervention: OMC 4 (4 days b.d. 20 mg omeprazole, 400 mg metronidazole, 250 mg clarithromycin followed by 6 days b.d. 20 mg omeprazole and placebo antibiotics)
Number of subjects: 76
Study 10930901 — intervention group
Group type: EXPERIMENTAL
Intervention: OMC 7 (7 days b.d. 20 mg omeprazole, 400 mg metronidazole, 250 mg clarithromycin followed by 3 days b.d. 20 mg omeprazole and placebo antibiotics)
Number of subjects: 76
Study 10930901 — intervention group
Group type: EXPERIMENTAL
Intervention: OMC 10 (10 days b.d. 20 mg omeprazole, 400 mg metronidazole, 250 mg clarithromycin)
Number of subjects: 76
Study 10930901 — intervention group
Group type: EXPERIMENTAL
Intervention: All three treatments (OMC 4, OMC 7, OMC 10)
Number of subjects: 76
Study 9298124 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased number of mast cells in non-involved skin
Number of subjects: 43
Study 9298124 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased number of CD3+ lymphocytes in non-involved skin
Number of subjects: 43
Study 9298124 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between mast cells in non-involved skin and duodenal intraepithelial lymphocytes
Number of subjects: 43
Study 9298124 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverse correlation between CD3+ lymphocytes in non-involved skin and duodenal mast cells
Number of subjects: 43
Study 8409033 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention communities
Number of subjects: 0
Study 8409033 — intervention group
Group type: COMPARATOR
Intervention: Control communities
Number of subjects: 0
Study 30715261 — intervention group
Group type: EXPERIMENTAL
Intervention: (Peg)IFN therapy
Number of subjects: 1058
Study 30715261 — intervention group
Group type: EXPERIMENTAL
Intervention: G3BP2 G-allele
Number of subjects: 1058
Study 29946007 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 1061
Study 29946007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1061
Study 27188919 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid contrast agent
Number of subjects: 66
Study 27188919 — intervention group
Group type: EXPERIMENTAL
Intervention: Semisolid contrast agent
Number of subjects: 66
Study 27188919 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid contrast agent in patients with severe hiatal hernia
Number of subjects: 66
Study 27188919 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid contrast agent in patients with mild hiatal hernia
Number of subjects: 66
Study 27188919 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid contrast agent in patients with no hiatal hernia
Number of subjects: 66
Study 23656176 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous patient-controlled analgesia
Number of subjects: 140
Study 23656176 — intervention group
Group type: COMPARATOR
Intervention: Intravenous injection
Number of subjects: 140
Study 22534523 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid extra-medial thickness
Number of subjects: 389
Study 20307215 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) - 1-3 injections of 1.25 mg
Number of subjects: 31
Study 20307215 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal triamcinolone acetonide (IVT) - 1-3 injections of 2 mg
Number of subjects: 31
Study 18562489 — intervention group
Group type: EXPERIMENTAL
Intervention: GH therapy administered subcutaneously at 0.05 mg/kg per day until growth velocity was 1 cm/6 months
Number of subjects: 29
Study 18562489 — intervention group
Group type: EXPERIMENTAL
Intervention: GH therapy in children with a mutation in PTPN11
Number of subjects: 29
Study 16331547 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Mandibular Advancer (FMA)
Number of subjects: 16
Study 16331547 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 16
Study 12356962 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracerebral fetal tissue grafting
Number of subjects: 0
Study 12356962 — intervention group
Group type: COMPARATOR
Intervention: Sham surgery
Number of subjects: 0
Study 10340734 — intervention group
Group type: EXPERIMENTAL
Intervention: Flammazine
Number of subjects: 74
Study 10340734 — intervention group
Group type: EXPERIMENTAL
Intervention: Flammacerium
Number of subjects: 74
Study 10340734 — intervention group
Group type: COMPARATOR
Intervention: Deflamol
Number of subjects: 74
Study 10340734 — intervention group
Group type: COMPARATOR
Intervention: Polyvidone-iodine
Number of subjects: 74
Study 8738857 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine (4 g twice daily) concurrent with valproic acid (250 mg)
Number of subjects: 6
Study 8738857 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine (4 g twice daily) staggered with valproic acid (250 mg, 3 hours apart)
Number of subjects: 6
Study 8738857 — intervention group
Group type: COMPARATOR
Intervention: Valproic acid alone (250 mg)
Number of subjects: 6
Study 1860196 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant tissue‐type plasminogen activator (rt‐PA)
Number of subjects: 180
Study 1860196 — intervention group
Group type: EXPERIMENTAL
Intervention: rt‐PA plus heparin
Number of subjects: 180
Study 1860196 — intervention group
Group type: EXPERIMENTAL
Intervention: streptokinase
Number of subjects: 180
Study 1860196 — intervention group
Group type: EXPERIMENTAL
Intervention: streptokinase plus heparin
Number of subjects: 180
Study 1860196 — intervention group
Group type: COMPARATOR
Intervention: heparin (when begun 12 hours after intravenous thrombolysis)
Number of subjects: 180
Study 1860196 — intervention group
Group type: COMPARATOR
Intervention: all treatment groups
Number of subjects: 180
Study 6137165 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide nasal spray
Number of subjects: 45
Study 6137165 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate nasal spray
Number of subjects: 45
Study 29471477 — intervention group
Group type: EXPERIMENTAL
Intervention: MapMyFitness application and Facebook-delivered health education intervention
Number of subjects: 10
Study 28431551 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Internet-based cognitive behavioural therapy (iCBT) intervention
Number of subjects: 92
Study 28431551 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face clinical care for tinnitus
Number of subjects: 92
Study 26763501 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior Therapy (BT)
Number of subjects: 188
Study 26763501 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 188
Study 26763501 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 188
Study 26763501 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive interventions (CT and CBT)
Number of subjects: 188
Study 24339310 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety condition
Number of subjects: 46
Study 24339310 — intervention group
Group type: EXPERIMENTAL
Intervention: Spring (n=25)
Number of subjects: 46
Study 24339310 — intervention group
Group type: EXPERIMENTAL
Intervention: Summer (n=21)
Number of subjects: 46
Study 24339310 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal differences
Number of subjects: 46
Study 22111350 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine 0.3 mg x kg(‐1)
Number of subjects: 30
Study 22111350 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine 0.6 mg x kg(‐1)
Number of subjects: 30
Study 22111350 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 30
Study 19400884 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 days of convalescence
Number of subjects: 0
Study 19400884 — intervention group
Group type: COMPARATOR
Intervention: 7 days of convalescence
Number of subjects: 0
Study 18004133 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 30
Study 15305553 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 1 (5 to 10 years)
Number of subjects: 120
Study 15305553 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 2 (11 to 20 years)
Number of subjects: 120
Study 15305553 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 3 (21 to 30 years)
Number of subjects: 120
Study 15305553 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 4 (31 to 40 years)
Number of subjects: 120
Study 15305553 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 5 (41 to 50 years)
Number of subjects: 120
Study 15305553 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 6 (51 years or older)
Number of subjects: 120
Study 15305553 — intervention group
Group type: COMPARATOR
Intervention: All age groups
Number of subjects: 120
Study 11374522 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical decompression with fusion
Number of subjects: 81
Study 11374522 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 81
Study 11374522 — intervention group
Group type: COMPARATOR
Intervention: Neck collar
Number of subjects: 81
Study 9543266 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training with 30% maximal inspiratory pressure (PI,max)
Number of subjects: 31
Study 9543266 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training with 10% maximal inspiratory pressure (PI,max)
Number of subjects: 31
Study 9543266 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training with 30% maximal inspiratory pressure (PI,max) and evaluated breathing pattern
Number of subjects: 31
Study 8311488 — intervention group
Group type: EXPERIMENTAL
Intervention: KW-2307 single administration at 10 mg/m2 escalated to 35 mg/m2
Number of subjects: 40
Study 8311488 — intervention group
Group type: EXPERIMENTAL
Intervention: KW-2307 repeated administration at 30 mg/m2 for 4 weeks
Number of subjects: 40
Study 8311488 — intervention group
Group type: EXPERIMENTAL
Intervention: KW-2307 (both administration types)
Number of subjects: 40
Study 8311488 — intervention group
Group type: EXPERIMENTAL
Intervention: KW-2307 single administration
Number of subjects: 40
Study 8311488 — intervention group
Group type: EXPERIMENTAL
Intervention: KW-2307 repeated administration
Number of subjects: 40
Study 3289791 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine
Number of subjects: 80
Study 3289791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 29746337 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 1044
Study 29746337 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 1044
Study 26555475 — intervention group
Group type: EXPERIMENTAL
Intervention: Air filtration units
Number of subjects: 56
Study 26555475 — intervention group
Group type: COMPARATOR
Intervention: Wood stove changeout
Number of subjects: 56
Study 26555475 — intervention group
Group type: COMPARATOR
Intervention: Placebo filter intervention
Number of subjects: 56
Study 25363835 — intervention group
Group type: EXPERIMENTAL
Intervention: AQW051, administered over a broad dose range (up to 200 mg single dose, 75 mg multiple daily doses)
Number of subjects: 180
Study 25363835 — intervention group
Group type: EXPERIMENTAL
Intervention: AQW051
Number of subjects: 180
Study 25363835 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 22729610 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic exercise (FIO(2) = 0.12)
Number of subjects: 8
Study 22729610 — intervention group
Group type: COMPARATOR
Intervention: Normoxic exercise (FIO(2) = 0.21)
Number of subjects: 8
Study 21743410 — intervention group
Group type: EXPERIMENTAL
Intervention: Test mouth-rinse containing chlorhexidine and cetylpyridinium chloride
Number of subjects: 36
Study 21743410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 19779705 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclosporin A
Number of subjects: 16
Study 19779705 — intervention group
Group type: COMPARATOR
Intervention: ART only (Control)
Number of subjects: 16
Study 16427198 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep pain
Number of subjects: 0
Study 16427198 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial pain
Number of subjects: 0
Study 15273337 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadolinium-enhanced MR imaging at 3 weeks
Number of subjects: 54
Study 15273337 — intervention group
Group type: COMPARATOR
Intervention: Biopsy at 6 months
Number of subjects: 54
Study 11292273 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based psychosocial nursing interventions (2 home visits after high psychological distress score)
Number of subjects: 433
Study 10211006 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane (3% end-expired concentration)
Number of subjects: 32
Study 10211006 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane (0.6% end-expired concentration)
Number of subjects: 32
Study 7948439 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 0
Study 7948439 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified what treatment)
Number of subjects: 0
Study 2892991 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical interferon‐beta (IFN‐beta) gel (10(5) U/g) 4 times daily applied locally during eruptions (about 10 days)
Number of subjects: 25
Study 2892991 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 30566636 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 ID PEP booster doses of 0.1 mL PCEV
Number of subjects: 303
Study 30566636 — intervention group
Group type: COMPARATOR
Intervention: 2 ID PEP booster doses of 0.1 mL PCEV
Number of subjects: 303
Study 30566636 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary vaccination with 2 ID doses of 0.1 mL PCEV
Number of subjects: 303
Study 29266260 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure bands
Number of subjects: 187
Study 29266260 — intervention group
Group type: COMPARATOR
Intervention: Sham bands
Number of subjects: 187
Study 26782228 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of BioPQQ™ per day for 12 weeks
Number of subjects: 41
Study 26782228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 24854829 — intervention group
Group type: EXPERIMENTAL
Intervention: Olfactory (SMELL: n = 8)
Number of subjects: 27
Study 24854829 — intervention group
Group type: EXPERIMENTAL
Intervention: Gustatory (TASTE: n = 10)
Number of subjects: 27
Study 24854829 — intervention group
Group type: EXPERIMENTAL
Intervention: Olfactory+gustatory (SMELL+TASTE: n = 9)
Number of subjects: 27
Study 22569211 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco Tactics website
Number of subjects: 184
Study 22569211 — intervention group
Group type: COMPARATOR
Intervention: 1-800-QUIT-NOW telephone line
Number of subjects: 184
Study 21155437 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium group (n = 30) received PB with a local anesthetic mixture (Lidocaine 2% + Bupivacaine 0.5%) to which was added 0.06 mg/Kg of rocuronium
Number of subjects: 60
Study 21155437 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 30) received PB with the same mixture to which was added saline
Number of subjects: 60
Study 17289893 — intervention group
Group type: EXPERIMENTAL
Intervention: PV701 (24x10(9) plaque‐forming units/m2 for the first dose, 120x10(9) plaque‐forming units/m2 for doses 2 to 6)
Number of subjects: 18
Study 17289893 — intervention group
Group type: EXPERIMENTAL
Intervention: PV701
Number of subjects: 18
Study 16332657 — intervention group
Group type: EXPERIMENTAL
Intervention: High calcium (1259 +/- 9 mg/d), high dairy (high/high)
Number of subjects: 12
Study 16332657 — intervention group
Group type: EXPERIMENTAL
Intervention: High calcium (1259 +/- 9 mg/d), low dairy (high/low)
Number of subjects: 12
Study 16332657 — intervention group
Group type: EXPERIMENTAL
Intervention: Low calcium (349 +/- 8 mg/d), low dairy (low/low)
Number of subjects: 12
Study 16332657 — intervention group
Group type: COMPARATOR
Intervention: High/high
Number of subjects: 12
Study 16332657 — intervention group
Group type: COMPARATOR
Intervention: High/low
Number of subjects: 12
Study 16332657 — intervention group
Group type: COMPARATOR
Intervention: Low/low
Number of subjects: 12
Study 11959610 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 10 mg/kg for 3 days
Number of subjects: 56
Study 11959610 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 20 mg/kg for 3 days
Number of subjects: 56
Study 10065781 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 12
Study 10065781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10065781 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary FSH
Number of subjects: 12